D.E. Shaw & Co’s Ultragenyx Pharmaceutical RARE Stock Holding History

D.E. Shaw & Co’s Portfolio RARE Stock Details RARE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Sell	-10,000	Closed	-$533K	–	3708
2017 Q3	$533K	Hold	10,000	–	–	﹤0.01%	2872
2017 Q2	$621K	Buy	+10,000	New	+$602K	﹤0.01%	2704
2016 Q1	–	Sell	-24,000	Closed	-$2.69M	–	3717
2015 Q4	$2.69M	Sell	24,000 -10,000	-29%	-$1,000K	﹤0.01%	1894
2015 Q3	$3.27M	Buy	34,000 +24,000	+240%	+$2.75M	﹤0.01%	1716
2015 Q2	$1.02M	Buy	+10,000	New	+$776K	﹤0.01%	2684

Other funds holding RARE

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return

FCM

Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return

D.E. Shaw & Co's RARE Position: Q2 2026 in Review

D.E. Shaw & Co increased its Ultragenyx Pharmaceutical (RARE) stake by 37% in Q2 2026, buying an estimated $11.7M and bringing the position to 1,730,193 shares worth $57.8M. The position accounts for 0.03% of the portfolio, ranked #684.

D.E. Shaw & Co first reported a position in RARE in Q1 2015 and has held it in 37 quarters since. The position peaked at $99M in Q4 2020. 311 funds tracked by Wall St. Rank hold RARE as of Q2 2026.

D.E. Shaw & Co held 1,730,193 shares of Ultragenyx Pharmaceutical worth $57.8M as of Q2 2026.
D.E. Shaw & Co bought 469,175 Ultragenyx Pharmaceutical shares in Q2 2026, an estimated $11.7M.
Ultragenyx Pharmaceutical made up 0.03% of D.E. Shaw & Co's portfolio in Q2 2026, its #684 holding.
D.E. Shaw & Co first reported a position in Ultragenyx Pharmaceutical in Q1 2015 and has held it in 37 quarters since.
D.E. Shaw & Co's Ultragenyx Pharmaceutical position peaked at $99M in Q4 2020.
311 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q2 2026.

Based on D.E. Shaw & Co's 13F filing for Q2 2026, filed 14 Aug 2026.